$JRSS
JRSIS HEALTH CARE Corp

2023 Q4 Form 10-Q Financial Statement

#000121390023087269 Filed on November 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $3.405M $13.57K
YoY Change 3718.6%
Cost Of Revenue $2.979M $377.3K
YoY Change
Gross Profit $426.2K $120.1K
YoY Change
Gross Profit Margin 12.52% 885.3%
Selling, General & Admin $482.4K $120.0K
YoY Change 278.43% -4.28%
% of Gross Profit 113.19% 99.91%
Research & Development $189.3K $36.20K
YoY Change
% of Gross Profit 44.41% 30.14%
Depreciation & Amortization $43.82K $10.00K
YoY Change 1957.28% 361.68%
% of Gross Profit 10.28% 8.33%
Operating Expenses $271.5K $130.0K
YoY Change 104.13% -1.86%
Operating Profit $154.7K -$119.1K
YoY Change -10.06%
Interest Expense -$53.38K
YoY Change
% of Operating Profit -34.51%
Other Income/Expense, Net $156.4K
YoY Change -9086.78%
Pretax Income $257.7K -$119.1K
YoY Change -665.61% -10.06%
Income Tax $8.980K
% Of Pretax Income 3.48%
Net Earnings $262.4K -$119.1K
YoY Change -675.92% -10.06%
Net Earnings / Revenue 7.71% -878.11%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share $0.00 -$0.02
COMMON SHARES
Basic Shares Outstanding 5.837M shares 5.837M shares
Diluted Shares Outstanding 5.837M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $118.1K $30.00K
YoY Change 101.48% 170.76%
Cash & Equivalents $118.1K $33.39K
Short-Term Investments
Other Short-Term Assets $420.1K $490.0K
YoY Change -42.96% -40.11%
Inventory $455.2K
Prepaid Expenses
Receivables $714.7K
Other Receivables $4.730K $2.836K
Total Short-Term Assets $1.834M $527.2K
YoY Change 129.57% -36.67%
LONG-TERM ASSETS
Property, Plant & Equipment $50.02K $30.84K
YoY Change 28.3% -22.77%
Goodwill
YoY Change
Intangibles $257.3K
YoY Change -15.13%
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $310.6K $37.55K
YoY Change 443.76% -38.94%
TOTAL ASSETS
Total Short-Term Assets $1.834M $527.2K
Total Long-Term Assets $310.6K $37.55K
Total Assets $2.145M $564.7K
YoY Change 150.54% -36.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $801.3K $8.000K
YoY Change 3142.64% 0.0%
Accrued Expenses $114.8K $10.00K
YoY Change 519.65% -42.95%
Deferred Revenue $218.3K
YoY Change
Short-Term Debt $983.0K $0.00
YoY Change
Long-Term Debt Due $18.71K
YoY Change -62.35%
Total Short-Term Liabilities $2.280M $90.97K
YoY Change 5174.52% 230.46%
LONG-TERM LIABILITIES
Long-Term Debt $24.95K $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $24.95K $0.00
YoY Change 1644.76% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.280M $90.97K
Total Long-Term Liabilities $24.95K $0.00
Total Liabilities $2.305M $90.97K
YoY Change 5061.5% 175.25%
SHAREHOLDERS EQUITY
Retained Earnings -$3.443M -$24.05M
YoY Change -85.48% 1.64%
Common Stock $8.259K $583.00
YoY Change -85.85% -99.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$137.4K $473.7K
YoY Change
Total Liabilities & Shareholders Equity $2.145M $564.7K
YoY Change 150.54% -36.82%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $262.4K -$119.1K
YoY Change -675.92% -10.06%
Depreciation, Depletion And Amortization $43.82K $10.00K
YoY Change 1957.28% 361.68%
Cash From Operating Activities $536.7K $10.00K
YoY Change 697.15% -98.85%
INVESTING ACTIVITIES
Capital Expenditures $1.480K $0.00
YoY Change -185.55% -100.0%
Acquisitions
YoY Change
Other Investing Activities $20.37K $0.00
YoY Change
Cash From Investing Activities $18.89K $0.00
YoY Change 998.26% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -568.4K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 536.7K 10.00K
Cash From Investing Activities 18.89K 0.000
Cash From Financing Activities -568.4K 0.000
Net Change In Cash -12.76K 10.00K
YoY Change -118.48% -128.91%
FREE CASH FLOW
Cash From Operating Activities $536.7K $10.00K
Capital Expenditures $1.480K $0.00
Free Cash Flow $535.2K $10.00K
YoY Change 675.04% -98.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
usd
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56013
dei Entity Registrant Name
EntityRegistrantName
JRSIS HEALTH CARE CORPORATION.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4562047
dei Entity Address Address Line1
EntityAddressAddressLine1
3/F Building A
dei Entity Address Address Line2
EntityAddressAddressLine2
De Run YuanNo. 19 Chang Yi Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Chang Ming ShuiWu Gui Shan
dei Entity Address City Or Town
EntityAddressCityOrTown
Zhong Shan City
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
528458
dei City Area Code
CityAreaCode
+86
dei Local Phone Number
LocalPhoneNumber
760-88963658
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5836659 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33387 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58616 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2836 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2987 usd
CY2023Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
490928 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
736393 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
527151 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
798850 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30844 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38989 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6705 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18138 usd
CY2023Q3 us-gaap Assets
Assets
564700 usd
CY2022Q4 us-gaap Assets
Assets
855977 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
24711 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1165 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1812 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6705 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16708 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
90969 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43231 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1430 usd
CY2023Q3 us-gaap Liabilities
Liabilities
90969 usd
CY2022Q4 us-gaap Liabilities
Liabilities
44661 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
583 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
583 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24510284 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24510284 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24049048 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23705746 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11912 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6195 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
473731 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
811316 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
564700 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
855977 usd
CY2023Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
13567 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
56884 usd
CY2023Q3 us-gaap Revenues
Revenues
13567 usd
us-gaap Revenues
Revenues
56884 usd
CY2023Q3 jrss Rentals And Leases
RentalsAndLeases
3411 usd
CY2022Q3 jrss Rentals And Leases
RentalsAndLeases
4861 usd
jrss Rentals And Leases
RentalsAndLeases
11389 usd
jrss Rentals And Leases
RentalsAndLeases
9282 usd
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81822 usd
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81821 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
245465 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
163643 usd
CY2023Q3 us-gaap Supplies Expense
SuppliesExpense
7621 usd
CY2022Q3 us-gaap Supplies Expense
SuppliesExpense
4927 usd
us-gaap Supplies Expense
SuppliesExpense
18398 usd
us-gaap Supplies Expense
SuppliesExpense
34195 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3985 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4004 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
12181 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
9619 usd
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
109 usd
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
319 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
490 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
816 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
33736 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
34362 usd
us-gaap Professional Fees
ProfessionalFees
106023 usd
us-gaap Professional Fees
ProfessionalFees
60850 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2016 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2166 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6240 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3671 usd
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
132700 usd
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
132460 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
400186 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
282069 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-119133 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-132460 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-343302 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-282069 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-119133 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-132460 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-343302 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-282069 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-119133 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-132460 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-343302 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-282069 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-119133 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-132460 usd
us-gaap Net Income Loss
NetIncomeLoss
-343302 usd
us-gaap Net Income Loss
NetIncomeLoss
-33675739 usd
CY2023Q3 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-874 usd
CY2022Q3 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-3741 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-5717 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-21298 usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-301922 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-118259 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-128719 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-337585 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33352519 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.023
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.059
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.07
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.023
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.059
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.07
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-8.228
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-8.228
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.023
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.059
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.298
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.023
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.059
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.298
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5836659 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5836659 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5836659 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4058356 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5836659 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5836659 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5836659 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4058356 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33102180 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2638816 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
208210 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
35949206 usd
CY2022Q2 jrss Loss From Discontinuing Operations
LossFromDiscontinuingOperations
-34984724 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-127290 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1056510 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
60000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-970560 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6356 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
989498 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-132460 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3741 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
860779 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
811316 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-119164 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-257 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
691895 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-105005 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5100 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
591990 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-119133 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
874 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
473731 usd
us-gaap Net Income Loss
NetIncomeLoss
-343302 usd
us-gaap Net Income Loss
NetIncomeLoss
-33675739 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-343302 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-282069 usd
us-gaap Depreciation
Depreciation
6240 usd
us-gaap Depreciation
Depreciation
3671 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
12181 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
490 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
us-gaap Share Based Compensation
ShareBasedCompensation
245465 usd
us-gaap Share Based Compensation
ShareBasedCompensation
163643 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-151 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3037 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-854 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-16711 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
75099 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
2001 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-647 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-1493 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20180 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-172305 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
3171627 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20180 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2999322 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46367 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-46367 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-2783041 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2829408 usd
jrss Shareholder Contribution To A Subsidiary
ShareholderContributionToASubsidiary
69260 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60000 usd
jrss Derivative Financial Instruments
DerivativeFinancialInstruments
7 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129267 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-867508 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-738241 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5049 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-276560 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25229 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-844887 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58616 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33387 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11084 usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
33387 usd
CY2022Q3 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
11084 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33387 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11084 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-13086 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
406544 usd
us-gaap Stock Issued1
StockIssued1
245465 usd
us-gaap Stock Issued1
StockIssued1
1056510 usd
jrss Shares Repurchase
SharesRepurchase
-970560 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
539200 shares
CY2023Q2 us-gaap Shares Issued
SharesIssued
1 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C. Use of estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>E. Concentration of Credit Risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. As of September 30, 2023 and as of December 31, 2022, no customer accounted for more than 5% of net accounts receivable. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited. For the nine months ended September 30, 2023, one customer accounted for 100% of total revenue. For the nine months ended September 30, 2022, no customer accounted for more than 10% of net revenue.</span></p>
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.70 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2023Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
74652 usd
us-gaap Other Expenses
OtherExpenses
981858 usd
jrss Expense Term Year
ExpenseTermYear
P3Y
jrss Compensation Expenses
CompensationExpenses
245465 usd
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.25 pure
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>O. Reclassification</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The comparative figures before April 1, 2022 have been reclassified to conform to current year presentation to reflect the disposal of a component of business derived from the recognition of a spin-off transaction on April 28, 2022.</span></p>
CY2023Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
539200 shares
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
42204 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44644 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11360 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5655 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30844 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38989 usd
us-gaap Depreciation
Depreciation
6240 usd
us-gaap Depreciation
Depreciation
3671 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1528 usd
CY2023Q3 jrss Net Lease Assets
NetLeaseAssets
6705 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6705 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6705 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
6705 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6705 usd
CY2023Q3 us-gaap Other Liabilities
OtherLiabilities
6705 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2008Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6705 usd
CY2008Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6705 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
3985 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4004 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
12181 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
9619 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
56884 usd
us-gaap Revenues
Revenues
56884 usd
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.25 pure
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
3913000 shares
CY2022Q2 us-gaap Partners Capital Account Units Sold In Private Placement
PartnersCapitalAccountUnitsSoldInPrivatePlacement
800000 shares
CY2022Q2 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
4713000 shares
jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2023Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
74652 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
981858 usd
jrss Compensation Expenses
CompensationExpenses
245465 usd
jrss Compensation Expenses
CompensationExpenses
163643 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
usd
CY2022Q1 jrss Owned Percentage
OwnedPercentage
1 pure
CY2022Q2 us-gaap Shares Issued
SharesIssued
3913000 shares
CY2022Q2 jrss Acquired Shares
AcquiredShares
800000 shares
CY2022Q2 jrss Owned Shares
OwnedShares
4713000 shares
CY2022Q2 jrss Common Stock Percentage
CommonStockPercentage
0.807 pure
CY2022Q2 jrss Total Share Issued
TotalShareIssued
600000 shares
CY2022Q2 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
60000 usd
CY2022Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.01
jrss Transfer Agreement Description
TransferAgreementDescription
Runteng entered into an agreement regarding a transfer of Jiarun’s equity with Zhang Junsheng. Pursuant to the transfer agreement, Runteng transferred to Mr. Zhang equity interest in Jiarun, representing 70% of equity interest in Jiarun and Mr. Zhang transferred to Runteng 539,200 shares of the Company’s common stock. On May 27, 2022, the Company cancelled the 539,200 shares of the Company’s common stock. Since this transaction required certain authoritative approval before effective, the publication of these transactions was delayed so as to obtain all parties consent and advance authoritative approval. As of May 27, 2022, the issued and outstanding share number of the Company was 5,836,657, the balance of the number of shares held by Mr. Zhang and Mr. Zhong were nil (0%) and 4,713,000 (80.7%), respectively.
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
10 shares
CY2023Q3 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
1 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5836659 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5836659 shares
jrss Substantial Loss
SubstantialLoss
343302 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24049048 usd
jrss Shares Repurchase
SharesRepurchase
usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
us-gaap Revenues
Revenues
usd
jrss Expense Term Year
ExpenseTermYear
P3Y
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Country
EntityAddressCountry
CN
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
CY2022Q3 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2023Q3 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
usd
us-gaap Other Noncash Expense
OtherNoncashExpense
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
jrss Shareholder Contribution To A Subsidiary
ShareholderContributionToASubsidiary
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
jrss Derivative Financial Instruments
DerivativeFinancialInstruments
usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001597892

Files In Submission

Name View Source Status
jrss-20230930_def.xml Edgar Link unprocessable
jrss-20230930_cal.xml Edgar Link unprocessable
0001213900-23-087269-index-headers.html Edgar Link pending
0001213900-23-087269-index.html Edgar Link pending
0001213900-23-087269.txt Edgar Link pending
0001213900-23-087269-xbrl.zip Edgar Link pending
f10q0923ex31-1_jrsishealth.htm Edgar Link pending
f10q0923ex31-2_jrsishealth.htm Edgar Link pending
f10q0923ex32-1_jrsishealth.htm Edgar Link pending
f10q0923ex32-2_jrsishealth.htm Edgar Link pending
f10q0923_jrsishealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jrss-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jrss-20230930_pre.xml Edgar Link unprocessable
jrss-20230930_lab.xml Edgar Link unprocessable
f10q0923_jrsishealth_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending